Novartis stands behind Zolgensma® for the treatment of children less than 2 years of age with spinal muscular atrophy.
A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.
Novartis announced the company’s financial results for the second quarter and first half of 2019.
Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.
[email protected] of the Novartis Foundation and @SteveDavisPATH on how we can achieve #HealthForAll by making digital t… https://t.co/d4rTCYqTSI
#BreakingNews: Novartis receives FDA priority review for investigational biologic therapy for the prevention of… https://t.co/k5LrYrQhpK
NEWS: The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI… https://t.co/49mJNlpYU9
This site is intended for a global audience.